The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes of FOLFIRINOX and gemcitabine plus nab-paclitaxel in patients with early recurrent pancreatic cancer after adjuvant S-1: A propensity score–matching analysis.
 
Naohiro Okano
Honoraria - Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - GlaxoSmithKline
 
Kentaro Sakamaki
No Relationships to Disclose
 
Takafumi Mie
No Relationships to Disclose
 
Kazuo Watanabe
No Relationships to Disclose
 
Satoshi Kobayashi
Honoraria - Bayer Yakuhin; Chugai Pharma; Eisai; GlaxoSmithKline; Lilly; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Eisai (Inst); Incyte (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Akiko Todaka
Honoraria - Nihon Servier; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
 
Yuko Suzuki
No Relationships to Disclose
 
Hidetoshi Kitamura
No Relationships to Disclose
 
Kazunari Tanaka
No Relationships to Disclose
 
Kei Nakagawa
Speakers' Bureau - Incyte
 
Keiko Kamei
No Relationships to Disclose
 
Kumiko Umemoto
Honoraria - Taiho Pharmaceutical; Taiho Pharmaceutical
 
Nobuaki Azemoto
No Relationships to Disclose
 
Yasuyuki Kawamoto
Honoraria - Incyte; Lilly; Merck; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Japan Agency for Medical Research and Development; Takeda
 
Hiroaki Yanagimoto
No Relationships to Disclose
 
Kunihiro Tsuji
No Relationships to Disclose
 
Hiroshi Imaoka
Honoraria - AstraZeneca; Kaneka Medix; Nihon Servier; Yakult Honsha
Consulting or Advisory Role - Nihon Servier
Research Funding - Ono Pharmaceutical
 
Takeshi Terashima
Speakers' Bureau - AstraZeneca; Bayer; Chugai Pharma; Daiichi Sankyo; Eisai; Novartis; Taiho Pharmaceutical
 
Makoto Ueno
Honoraria - AstraZeneca; Chugai Pharma; Incyte; MSD; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Novocure
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); Incyte (Inst); JPH Clinical Development (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Junji Furuse
Honoraria - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Fujifilm; Kyowa Hakko Kirin; Lilly Japan; Merck; MSD; Mylan; Nihon Servier; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Merck; MSD; Mundipharma; OncoTherapy Science; Ono Pharmaceutical; Takara Bio; Yakult Honsha
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Incyte (Inst); J-Pharma (Inst); Merck (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)